**Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than 10 years of innovations carried out by African and European organizations working through public-private partnerships.
This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and have been submitted to regulators. The FDC is being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA, with decisions anticipated in early 2025, which will be followed by WHO consideration for P
This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and have been submitted to regulators. The FDC is being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA, with decisions anticipated in early 2025, which will be followed by WHO consideration for prequalification.
The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach
Our FDC provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach
borja
2 months ago